Prime Medicine, Inc. (PRME) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Prime Medicine, Inc. is a biotechnology company developing Prime Editing technology for genetic diseases. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of July 31, 2026, there were 181,376,856 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $1.15 million | $2.01 million | $2.57 million |
| Net Loss | $(42.11) million | $(91.23) million | $(104.48) million |
| Net Loss Per Share | $(0.24) | $(0.51) | $(0.81) |
| Operating Expenses | $44.44 million | $95.95 million | $108.34 million |
| Cash & Short-Term Investments | $95.1 million (as of June 30, 2026) | ||
| Accumulated Deficit | $979.6 million (as of June 30, 2026) |
Liquidity: The company reported cash, cash equivalents, and short-term investments of $95.1 million. Net cash used in operating activities for the six months ended June 30, 2026, was $83.76 million.
Material Changes vs. Prior Period
- Expense Reduction: Research and development (R&D) expenses decreased by $14.4 million year-over-year (YTD), primarily due to a $7.4 million reduction in personnel costs following a workforce reduction in May 2025 and a $5.7 million decrease in research costs as programs advanced toward clinical trials.
- Legal Costs: General and administrative (G&A) expenses increased by $2.0 million YTD, driven by a $4.2 million increase in professional and consultant fees, largely attributed to arbitration-related legal expenses.
- Investment Portfolio: Short-term investments decreased from $114.6 million at year-end 2025 to $47.6 million at June 30, 2026, reflecting maturities and purchases.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for 12 months from the filing date. The company expects to incur operating losses for the foreseeable future and relies on obtaining additional financing to meet obligations.
- Clinical Progress:
- PM577a (Wilson Disease): Received CTA clearance in New Zealand (June 2026) and FDA IND clearance (July 2026), enabling global Phase 1/2 trials.
- PM647 (AATD): On track for IND/CTA submission in Q3 2026.
- PM359 (CGD): Received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in June 2026; Biologics License Application planned for H1 2027.
- Legal Resolution: On July 6, 2026, an arbitration tribunal issued a final award in favor of Prime Medicine against Beam Therapeutics, declaring that the AATD program (PM647) is within Prime's "Field" and denying Beam's claims for damages or injunctive relief.
- Capital Strategy: The company plans to fund operations through its "at-the-market" (ATM) offering program (up to $300 million authorized) and potential equity or debt financings.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion given the "substantial doubt" going concern disclosure and the $95.1 million liquidity position.
- Financing Terms: Review the status of the ATM program and any pending equity/debt financing to assess dilution risks.
- Legal Exposure: Confirm that the Beam Therapeutics arbitration resolution is final and that no further appeals or related IP disputes are pending.
- Collaboration Revenue: Monitor the recognition of revenue from the Bristol-Myers Squibb (BMS) collaboration, which currently represents the primary revenue stream ($64.0 million in unsatisfied performance obligations).
- Regulatory Milestones: Track the actual submission dates for PM647 (AATD) and the initiation of PM577a (Wilson Disease) clinical trials against management's Q3 2026 targets.